Biotech Solutions Through Viral Intelligence
Discover our breakthrough therapies revolutionizing treatments for complex neurological diseases.
SoziOZ
Oncolytic Therapy
SoziOZ is an innovative oncolytic therapy targeting malignant brain tumors. It is specifically engineered to cross the BBB and activate the immune system, offering a breakthrough for conditions like glioblastoma and pediatric CNS tumors.
Key Benefits:
High tumor specificity – targets only cancer cells.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
pZiOZ
Precision mRNA Therapy
pZiOZ is a dual-purpose mRNA platform for neuroprotection and repair. It combines next-gen mRNA vaccine technology with safe and scalable gene therapy capabilities.
Key Benefits:
Dual application for vaccines and therapy.
Rapid, scalable production.
Effective system reach.
EviOZ
RNA Viral Vector
EviOZ is a first-in-class RNA viral vector offering enhanced capabilities for gene therapies. It overcomes traditional AAV limitations by providing higher genetic payloads, reduced immune reactions, and BBB penetration.
Key Benefits:
Carries up to 10 kb of genetic material.
Crosses both the BBB and BRB (blood-retinal barrier).
Low immunogenicity and enhanced stability.
pZiOZ – Precision mRNA Therapy
pZiOZ is a dual-purpose mRNA platform for neuroprotection and repair. It combines next-gen mRNA vaccine technology with safe and scalable gene therapy capabilities.
Key Benefits:
Dual application for vaccines and therapy.
Rapid, scalable production.
Effective system reach.
EviOZ – RNA Viral Vector
EviOZ is a first-in-class RNA viral vector offering enhanced capabilities for gene therapies. It overcomes traditional AAV limitations by providing higher genetic payloads, reduced immune reactions, and BBB penetration.
Key Benefits:
Carries up to 10 kb of genetic material.
Crosses both the BBB and BRB (blood-retinal barrier).
Low immunogenicity and enhanced stability.
Key Milestones 2024-2026
Our developments
pipeline
At iOZ Biotech, we are advancing precision-engineered viral therapies through a clear roadmap, bringing hope and transformative solutions to complex neurological diseases. Explore the key milestones shaping the future of brain health.
2024
Preclinical Studies for SoziOZ
in Glioblastoma
- Initiating preclinical testing for SoziOZ, our innovative oncolytic viral therapy, to demonstrate its ability to cross the blood-brain barrier (BBB) and target glioblastoma.
- These studies will focus on tumor specificity, immune activation, and overall safety to set the foundation for human trials.
2025
Clinical Phase 1 Trials for Glioblastoma at MSK (Memorial Sloan Kettering Cancer Center)
- Launching Phase 1 trials for SoziOZ, targeting glioblastoma patients.
- Primary goals: Assess safety, optimal dosing, and initial efficacy in treating one of the deadliest forms of brain cancer.
- Conducted at MSK, a world-renowned institution for cancer research and treatment.
2026
Phase 2 Studies for GBM in Brazil and the US
- Expanding clinical trials to Phase 2, focusing on larger patient cohorts to evaluate SoziOZ’s efficacy and further refine treatment protocols.
- Trials will be conducted in collaboration with leading medical centers in Brazil and the United States, emphasizing global accessibility and impact.
Use of Proceeds
Seed phase
$3M for IND filing and early-stage trials.
Serie A
$25M for manufacturing and clinical advancements.
Serie B
$40M for Phase 2 trials and market expansion.
Contact
Get in Touch
Reach out to join our mission to transform brain health.
Direct Contact: contact@ioz.bio
© 2025 iOZ. All rights reserved.
Powered by Sthorm.io
Contact
Get in Touch
Reach out to join our mission to transform brain health.
Direct Contact:contact@ioz.bio
© 2025 iOZ. All rights reserved.
Powered by Sthorm.io
SoziOZ
Oncolytic Therapy
SoziOZ is an innovative oncolytic therapy targeting malignant brain tumors. It is specifically engineered to cross the BBB and activate the immune system, offering a breakthrough for conditions like glioblastoma and pediatric CNS tumors.
Key Benefits:
High tumor specificity – targets only cancer cells.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
SoziOZ
Oncolytic Therapy
SoziOZ is an innovative oncolytic therapy targeting malignant brain tumors. It is specifically engineered to cross the BBB and activate the immune system, offering a breakthrough for conditions like glioblastoma and pediatric CNS tumors.
Key Benefits:
High tumor specificity – targets only cancer cells.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
SoziOZ
Oncolytic Therapy
pZiOZ is a dual-purpose mRNA platform for neuroprotection and repair. It combines next-gen mRNA vaccine technology with safe and scalable gene therapy capabilities.
Key Benefits:
Dual application for vaccines and therapy.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
SoziOZ
Oncolytic Therapy
pZiOZ is a dual-purpose mRNA platform for neuroprotection and repair. It combines next-gen mRNA vaccine technology with safe and scalable gene therapy capabilities.
Key Benefits:
Dual application for vaccines and therapy.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
SoziOZ
Oncolytic Therapy
SoziOZ is an innovative oncolytic therapy targeting malignant brain tumors. It is specifically engineered to cross the BBB and activate the immune system, offering a breakthrough for conditions like glioblastoma and pediatric CNS tumors.
Key Benefits:
High tumor specificity – targets only cancer cells.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
SoziOZ
Oncolytic Therapy
SoziOZ is an innovative oncolytic therapy targeting malignant brain tumors. It is specifically engineered to cross the BBB and activate the immune system, offering a breakthrough for conditions like glioblastoma and pediatric CNS tumors.
Key Benefits:
High tumor specificity – targets only cancer cells.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
Key Milestones 2024-2026
Our developments
pipeline
Explore the key milestones shaping the future of brain health.
2024
Preclinical Studies for SoziOZ
in Glioblastoma
- Initiating preclinical testing for SoziOZ, our innovative oncolytic viral therapy, to demonstrate its ability to cross the blood-brain barrier (BBB) and target glioblastoma.
- These studies will focus on tumor specificity, immune activation, and overall safety to set the foundation for human trials.
2025
Clinical Phase 1 Trials for Glioblastoma at MSK (Memorial Sloan Kettering Cancer Center)
- Launching Phase 1 trials for SoziOZ, targeting glioblastoma patients.
- Primary goals: Assess safety, optimal dosing, and initial efficacy in treating one of the deadliest forms of brain cancer.
- Conducted at MSK, a world-renowned institution for cancer research and treatment.
2026
Phase 2 Studies for GBM in Brazil and the US
- Expanding clinical trials to Phase 2, focusing on larger patient cohorts to evaluate SoziOZ’s efficacy and further refine treatment protocols.
- Trials will be conducted in collaboration with leading medical centers in Brazil and the United States, emphasizing global accessibility and impact.
Biotech Solutions Through Viral Intelligence
Discover our breakthrough therapies revolutionizing treatments for complex neurological diseases.
SoziOZ
Oncolytic Therapy
SoziOZ is an innovative oncolytic therapy targeting malignant brain tumors. It is specifically engineered to cross the BBB and activate the immune system, offering a breakthrough for conditions like glioblastoma and pediatric CNS tumors.
Key Benefits:
High tumor specificity – targets only cancer cells.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
pZiOZ
Precision mRNA Therapy
pZiOZ is a dual-purpose mRNA platform for neuroprotection and repair. It combines next-gen mRNA vaccine technology with safe and scalable gene therapy capabilities.
Key Benefits:
Dual application for vaccines and therapy.
Rapid, scalable production.
Effective system reach.
EviOZ
RNA Viral Vector
EviOZ is a first-in-class RNA viral vector offering enhanced capabilities for gene therapies. It overcomes traditional AAV limitations by providing higher genetic payloads, reduced immune reactions, and BBB penetration.
Key Benefits:
Carries up to 10 kb of genetic material.
Crosses both the BBB and BRB (blood-retinal barrier).
Low immunogenicity and enhanced stability.
pZiOZ – Precision mRNA Therapy
pZiOZ is a dual-purpose mRNA platform for neuroprotection and repair. It combines next-gen mRNA vaccine technology with safe and scalable gene therapy capabilities.
Key Benefits:
Dual application for vaccines and therapy.
Rapid, scalable production.
Effective system reach.
EviOZ – RNA Viral Vector
EviOZ is a first-in-class RNA viral vector offering enhanced capabilities for gene therapies. It overcomes traditional AAV limitations by providing higher genetic payloads, reduced immune reactions, and BBB penetration.
Key Benefits:
Carries up to 10 kb of genetic material.
Crosses both the BBB and BRB (blood-retinal barrier).
Low immunogenicity and enhanced stability.
Key Milestones 2024-2026
Our developments
pipeline
Explore the key milestones shaping the future of brain health.
2024
Preclinical Studies for SoziOZ
in Glioblastoma
- Initiating preclinical testing for SoziOZ, our innovative oncolytic viral therapy, to demonstrate its ability to cross the blood-brain barrier (BBB) and target glioblastoma.
- These studies will focus on tumor specificity, immune activation, and overall safety to set the foundation for human trials.
2025
Clinical Phase 1 Trials for Glioblastoma at MSK (Memorial Sloan Kettering Cancer Center)
- Launching Phase 1 trials for SoziOZ, targeting glioblastoma patients.
- Primary goals: Assess safety, optimal dosing, and initial efficacy in treating one of the deadliest forms of brain cancer.
- Conducted at MSK, a world-renowned institution for cancer research and treatment.
2026
Phase 2 Studies for GBM in Brazil and the US
- Expanding clinical trials to Phase 2, focusing on larger patient cohorts to evaluate SoziOZ’s efficacy and further refine treatment protocols.
- Trials will be conducted in collaboration with leading medical centers in Brazil and the United States, emphasizing global accessibility and impact.
Use of Proceeds
Seed phase
$3M for IND filing and early-stage trials.
Serie A
$25M for manufacturing and clinical advancements.
Serie B
$40M for Phase 2 trials and market expansion.
Contact
Get in Touch
Reach out to join our mission to transform brain health.
Direct Contact: contact@ioz.bio
© 2025 iOZ. All rights reserved.
Powered by Sthorm.io
SoziOZ
Oncolytic Therapy
SoziOZ is an innovative oncolytic therapy targeting malignant brain tumors. It is specifically engineered to cross the BBB and activate the immune system, offering a breakthrough for conditions like glioblastoma and pediatric CNS tumors.
Key Benefits:
High tumor specificity – targets only cancer cells.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
SoziOZ
Oncolytic Therapy
pZiOZ is a dual-purpose mRNA platform for neuroprotection and repair. It combines next-gen mRNA vaccine technology with safe and scalable gene therapy capabilities.
Key Benefits:
Dual application for vaccines and therapy.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
SoziOZ
Oncolytic Therapy
SoziOZ is an innovative oncolytic therapy targeting malignant brain tumors. It is specifically engineered to cross the BBB and activate the immune system, offering a breakthrough for conditions like glioblastoma and pediatric CNS tumors.
Key Benefits:
High tumor specificity – targets only cancer cells.
Penetrates the BBB – a challenge for most therapies.
Series B: $40M for Phase 2 trials and market expansion.
Key Milestones 2024-2026
Our developments
pipeline
Explore the key milestones shaping the future of brain health.
2024
Preclinical Studies for SoziOZ
in Glioblastoma
- Initiating preclinical testing for SoziOZ, our innovative oncolytic viral therapy, to demonstrate its ability to cross the blood-brain barrier (BBB) and target glioblastoma.
- These studies will focus on tumor specificity, immune activation, and overall safety to set the foundation for human trials.
2025
Clinical Phase 1 Trials for Glioblastoma at MSK (Memorial Sloan Kettering Cancer Center)
- Launching Phase 1 trials for SoziOZ, targeting glioblastoma patients.
- Primary goals: Assess safety, optimal dosing, and initial efficacy in treating one of the deadliest forms of brain cancer.
- Conducted at MSK, a world-renowned institution for cancer research and treatment.
2026
Phase 2 Studies for GBM in Brazil and the US
- Expanding clinical trials to Phase 2, focusing on larger patient cohorts to evaluate SoziOZ’s efficacy and further refine treatment protocols.
- Trials will be conducted in collaboration with leading medical centers in Brazil and the United States, emphasizing global accessibility and impact.